Wearable health tracking for advanced solid tumor treatment
Part of Cancer clinical trials.
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage III or IV) solid tumor cancer that cannot be cured with standard treatments.
- You have not yet received any treatment for metastatic cancer (first-line treatment only).
- You are willing and able to wear a small device and use a smartphone app to track your health.
- You have a mobile device with internet access and an email account.
- You do not have a pacemaker, defibrillator, or similar implanted electronic device.
- You are able to fill out questionnaires about your quality of life, nutrition, and mental health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests an early, first-in-people treatment (XT-0528) for people with advanced solid cancers that cannot be removed or have spread. The goal is to check safety and find out what doses might work, and it may help you if standard options are no longer available.
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
This trial tests if a wearable device paired with a smartphone app can help monitor symptoms in cancer survivors. The goal is to improve how we track and manage symptoms during and after treatment.
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
This trial checks if switching hormone therapy when ctDNA levels rise can help women with ER+/HER2- metastatic breast cancer. ctDNA is a tumor signal found in blood that may show early signs of resistance before scans do.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.